Form 4: Sensei Biotherapeutics Director Receives Stock Options
Director Equity Grant
Director Phillip B. Donenberg was granted 12,500 stock options in Sensei Biotherapeutics, Inc. as part of his compensation.
Summary
- Director Phillip B. Donenberg received a grant of 12,500 stock options on June 10, 2026.
- The options have an exercise price of $11.41 per share.
- The options vest in 12 equal monthly installments over a one-year period, becoming fully vested on June 10, 2027.
- The expiration date for these options is June 9, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility affecting the value of the underlying common stock.
- Dependence on the director's continuous service for the full vesting of the options.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.
Comparison to Industry Standards
- The use of monthly vesting over one year is a common retention and incentive structure for board members in small-cap biotech firms.
- The grant size is consistent with standard director compensation packages for companies of similar market capitalization.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Phillip B. Donenberg granted Power of Attorney to Christopher Gerry and Josiah Craver for SEC filing purposes. | 04/13/2026 | Standard administrative procedure to ensure timely compliance with Section 16 reporting requirements. |
Stakeholder Impact
- Minor dilution impact on existing shareholders upon potential future exercise of options.
Next Steps
- Vesting of options in monthly installments through June 2027.
Key Dates
| Date | Description |
|---|---|
| 04/13/2026 | Date of Power of Attorney execution. |
| 06/10/2026 | Date of option grant and earliest transaction. |
| 06/10/2027 | Full vesting date of the options. |
| 06/09/2036 | Expiration date of the options. |
Keywords
Sensei Biotherapeutics, SNSE, Director Compensation, Stock Options, Insider Transaction, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.